Agios Pharma (NASDAQ:AGIO) reported Q4 EPS of ($4.23), $2.86 worse than the analyst estimate of ($1.37). Revenue for the quarter came in at $14.24 million versus the consensus estimate of $4.54 million.
Agios Pharma (NASDAQ:AGIO) reported Q4 EPS of ($4.23), $2.86 worse than the analyst estimate of ($1.37). Revenue for the quarter came in at $14.24 million versus the consensus estimate of $4.54 million.